AIM ImmunoTech Inc. (AIM)
| Market Cap | 7.87M +10.0% |
| Revenue (ttm) | 95,000 -21.5% |
| Net Income | -14.27M |
| EPS | -2.14 |
| Shares Out | 30.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 426,898 |
| Open | 0.2590 |
| Previous Close | 0.2570 |
| Day's Range | 0.2549 - 0.2623 |
| 52-Week Range | 0.2100 - 2.8880 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 9.00 (+3,380.28%) |
| Earnings Date | Aug 10, 2026 |
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also ... [Read more]
Financial Performance
In 2025, AIM ImmunoTech's revenue was $88,000, a decrease of -48.24% compared to the previous year's $170,000. Losses were -$13.96 million, -19.41% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AIM stock is "Buy." The 12-month stock price target is $9.0, which is an increase of 3,380.28% from the latest price.
News
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article
Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge
AIM ImmunoTech Quarterly report: Q2 2026
AIM ImmunoTech has published its Q2 2026 quarterly earnings report on August 7, 2026.
AIM ImmunoTech Earnings release: Q2 2026
AIM ImmunoTech released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection Point
Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December...
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer CEO Thomas Equels discusses recent cli...
AIM ImmunoTech Proxy statement: Proxy filing
AIM ImmunoTech filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer develo...
AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences
LOS ANGELES--(BUSINESS WIRE)-- #aimsportsgroup--AIM Sports Group hosted the SoCal Cup ‘Showcase' tournament, one of the nation's leading tournament series for youth club volleyball, at the Los Angeles...
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series bei...
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancer Study results expected to support design and initiation of ...
AIM ImmunoTech Registration statement: Registration filing
AIM ImmunoTech filed a registration statement on June 18, 2026, providing details about a securities offering with the SEC.
AIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay Area
GUANGZHOU, China , June 17, 2026 (GLOBE NEWSWIRE) -- As global capital, industrial transformation, and cross border trade realign around new growth corridors, AIM Talks China 2026 convened investors, ...
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple...
AIM ImmunoTech Proxy statement: Proxy filing
AIM ImmunoTech filed a proxy statement on June 15, 2026, providing details for shareholder voting and corporate governance matters.
Infosys Collaborates with CMMI Institute to Shape Enterprise AI Maturity Framework; Achieves Milestone Recognition
As a pilot participant, Infosys contributed to shaping the CMMI AI Maturity (AIM) framework – bringing enterprise-scale AI practices, governance models, and real-world deployment insights – powered by...
AIM ImmunoTech Inc trading resumes
09:50 EDT AIM ImmunoTech (AIM) Inc trading resumes
AIM ImmunoTech announces $2.65M registered direct offering
AIM ImmunoTech (AIM) announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross...
AIM ImmunoTech Inc trading halted, news pending
09:27 EDT AIM ImmunoTech (AIM) Inc trading halted, news pending
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”), today announced that it has entered into definitive agreements for a registered direc...
AIM ImmunoTech registers to sell 31.29M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 31.29M shares of common stock. The company is not selling any…
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Company remains on track for a planned December 2026 evaluation of the clinical trial's primary endpoint Company remains on track for a planned December 2026 evaluation of the clinical trial's primary...
AIM ImmunoTech Registration statement: Registration filing
AIM ImmunoTech filed a registration statement on June 8, 2026, providing details about a securities offering with the SEC.
AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness
Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen's previously published antiviral research
AIM ImmunoTech enrolls final subject in pancreatic cancer development program
AIM ImmunoTech (AIM) announced enrollment of the final subject in its pancreatic cancer development program, barring disqualifying pre-treatment circumstances. The final planned subject is scheduled f...
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Trea...